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Abstract
Background: Pro-coagulant membrane microvesicles (MV) derived from platelets and leukocytes are shed into the
circulation following receptor-mediated activation, cell-cell interaction, and apoptosis. Platelets are sentinel markers of toll-
like receptor 4 (TLR4) activation. Experiments were designed to evaluate the time course and mechanism of direct
interactions between platelets and leukocytes following acute activation of TLR4 by bacterial lipopolysaccharide (LPS).
Methodology/Principal Findings: Blood from age-matched male and female wild type (WT) and TLR4 gene deleted (dTLR4)
mice was incubated with ultra-pure E. coli LPS (500 ng/ml) for up to one hour. At designated periods, leukocyte antigen
positive platelets, platelet antigen positive leukocytes and cell-derived MV were quantified by flow cytometry. Numbers of
platelet- or leukocyte-derived MV did not increase within one hour following in vitro exposure of blood to LPS. However,
with LPS stimulation numbers of platelets staining positive for both platelet- and leukocyte-specific antigens increased in
blood derived from WT but not dTLR4 mice. This effect was blocked by inhibition of TLR4 signaling mediated by My88 and
TRIF. Seven days after a single intravenous injection of LPS (500 ng/mouse or 20 ng/gm body wt) to WT mice, none of the
platelets stained for leukocyte antigen. However, granulocytes, monocytes and apoptotic bodies stained positive for
platelet antigens.
Conclusions/Significance: Within one hour of exposure to LPS, leukocytes exchange surface antigens with platelets
through TLR4 activation. In vivo, leukocyte expression of platelet antigen is retained after a single exposure to LPS following
turn over of the platelet pool. Acute expression of leukocyte antigen on platelets within one hour of exposure to LPS and
the sustained expression of platelet antigen on leukocytes following a single acute exposure to LPS in vivo explains, in part,
associations of platelets and leukocytes in response to bacterial infection and changes in thrombotic propensity of the
blood.
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Introduction
Acute and chronic infection, especially that induced by Gram-
negative bacteria is associated with increased risk of thrombosis
and atherosclerotic disease [1,2,3,4,5]. Little is known about the
underlying cellular mechanisms responsible for these risks.
Lipopolysaccharide (LPS), a component of the cell wall of
Gram-negative bacteria, is an antigen which initiates inflammation
and innate immune responses by interacting with Toll-like
receptor 4 (TLR4). TLR4 is expressed on the surface of cells,
including leukocytes and platelets [6,7,8]. Under physiological
conditions, platelets and leukocytes circulate in quiescent state and
do not interact with each other. However, once activated under
pathophysiological conditions such as those associated with
infection, platelets change shape, secrete prothrombogenic inflam-
matory and cellular adhesion molecules from alpha- and dense-
granules which cause the platelets to adhere to each other or to
leukocytes and/or vascular endothelium [9,10,11,12]. The
physiological consequences of stimuli associated with infection,
like LPS stimulation, are acute but can be sustained. For example,
half-life of platelets was shortened and the activation state of newly
formed platelets from bone marrow megakaryocytes increased
within seven days following a single acute intravenous injection of
LPS in mice [13,14]. However, cellular events, specifically those
occurring among blood elements, contributing to the shortened
half-life and increased activation state of platelets remains to be
clarified.
One mechanism offered to explain how infection contributes to
the onset and progression of cardiovascular diseases is through
increased production of proinflammatory cytokines [1,3]. How-
ever, this explanation does not address how the production of
inflammatory cytokines might proceed nor does it identity the cell
types which are targets for the LPS stimulation. Platelets may
represent one of the first blood borne elements to react to LPS
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occur prior to sustained changes in circulating levels of cytokines
[14]. Alternatively, comparable activation of leukocyte as well as
platelet result in formation of cell-derived microvesicles (MV)
which may contribute to increased thrombogenic propensity of the
blood, pro-inflammatory immune processes and thus cardiovas-
cular risk [15,16,17,18,19,20,21,22]. Clarifying the interactions of
these blood elements (platelets and leukocytes) in the setting of
TLR4 activation might provide insight into how infection initiates
or facilitates progression of cardiovascular disease.
MV are cell membrane-derived vesicles ranging in size from 0.1
to 1 micron in diameter which are shed in response to cellular
activation, cell-cell interaction and apoptosis [23,24,25,26,27].
These cell-derived vesicles are an interface of activation between
cellular components of the blood with the vascular wall and
between soluble components of the blood associated with
immunity including response to infection [24,28,29]. For example,
phosphatidylserine (PS) on the surface of MV provides catalytic
sites for prothrombinase complex to generate thrombin needed for
the conversion of fibrinogen to fibrin in formation of clots
[25,30,31]. Furthermore, exposure of diluted blood to LPS in vitro
increased production of platelet-derived as well as tissue factor
positive MV within 3 to 6 hours [32,33,34]. While those
experiments provide evidence that LPS modulates platelet
activation, they do not provide any insight about the interactions
of platelet with other blood elements within the earliest stages of
activation especially at time points prior to the period when
measurable changes in circulating cytokines are observed in vivo
[14]. Therefore, the present study was designed to test the
hypothesis that acute exposure to a sentinel dose of LPS would
induce MV production and exchange of specific proteins/
receptors between platelets and leukocytes via TLR4 activation.
MV transport of biologically active cell contents including cell
surface receptors among cells were identified using antibodies
specific for cell antigens (i.e. CD41 or CD45, which is platelet- or
leukocyte-specific antigens respectively) [24]; MV derived from
platelets and/or leukocytes were distinguished by cell specific
fluorescein conjugated antigen staining using calibrated flow
cytometry.
Materials and Methods
Animals
Four to eight month old, male and female C57BL10SnJ mice
(wild type, WT) and C57BL10ScN mice homozygous for deletion
of TLR4 (dTLR4) were obtained from the Jackson Laboratory,
Bar Harbor, Maine. These mice do not express the IL-12Rb2
mutation that was originally described for this strain [35]. Mice of
each sex and age were used randomly in each of the various
protocols. Mice were housed in a temperature-controlled envi-
ronment (2262uC; 5565% relative humidity), 12/12 light/dark
cycle, and fed standard chow. Experiments were approved by the
Institutional Animal Care and Use Committee, Mayo Clinic,
Rochester, MN.
Reagents
Ultra-pure E.coli lipopolysaccharide (LPS, 0111:B4 strain-
TLR4 ligand, product number tlrl-pelps), pepinh-MyD (product
number tlrl-pimyd) or pepinh-TRIF (product number tlrl-pitrif)
inhibitory peptide (InvivoGen, San Diego, CA) were prepared as
suggested by the supplier. Mouse thrombin and bovine serum
albumin were purchased from Sigma Chemical Co., St. Louis,
MO, USA. Cellular origin of antigens was determined using
platelet (rat anti-mouse CD41 antibody) and total leukocyte (rat
anti-mouse CD45 antibody) membrane specific fluorescein
conjugated {Phycoerythrin (PE)- or fluorescein isothiocyanate
(FITC)-} antibodies by flow cytometry. PE- or FITC-conjugated
Annexin-V and matched isotype control antibodies were pur-
chased from BD PharMingen International, San Diego, CA. All
other reagents and solvents used in this study were of analytical/
reagent grade.
Experimental design and blood collection
Blood was collected from the retro-orbital sinus plexus (250–
300 mL/mouse) of wild type and dTLR4 mice through siliconized
capillary tubes coated with hirudin (thrombin inhibitor) and
soybean trypsin inhibitor (STI, Factor Xa inhibitor) into 1.5 mL
polypropylene tubes containing 20 mL of 100 mM hirudin and
1 mM STI [13]. For in vitro experiments, anticoagulated blood was
aliquoted into pairs of tubes within 30 min after collection so that
measurements from a vehicle-treated, control tube and LPS-
treated tube could be analyzed from each mouse at each time
point. Vehicle (saline) or LPS (500 ng/mL) was added to one of
each paired aliquots of blood. At designated time points (5, 30, and
60 minutes) after addition of vehicle or LPS, 10 mL whole blood
from each aliquot was diluted into 990 mL (1:100) HEPES/
HANKS’ buffer (130 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl2,
0.8 mM MgSO4, 0.44 mM Na2HPO4, 20 mM HEPES, pH 7.4)
with 1 mg/ml albumin and 1 mM STI for staining of platelets
positive for leukocyte antigen and leukocyte positive for platelet
antigen. The remaining blood was used to prepare platelet free
plasma (PFP) for MV analysis.
For in vivo experiments, male mice (8 month of age) received a
single injection of LPS (500 ng/mouse or 20 ng/gm body weight)
into the tail vein. Seven days after the injection, blood was
collected as described above. For analysis of platelet antigen
positive leukocyte sub-populations, flow cytometry was triggered
with total leukocyte marker CD45-conjugated with allophycocya-
nin (CD45-APC). All CD45 positive events containing granulo-
cytes, monocytes, lymphocytes and apoptotic bodies were
separated by light forward and side scatter blot analysis and gated
each sub-type of leukocytes based on their size. Each gate was
verified using cell specific antibodies (CD11b for granulocytes,
CD14 for monocytes and CD3 for T-lymphocytes and CD19 for
B-lymphocytes. Differential leukocyte populations were then
subjected to two-color analysis to differentiate leukocytes positive
for phosphatidylserine and platelet antigen (annexin-V-FITC vs
CD41-PE) from leukocytes negative for phosphatidylserine and
platelet antigen. Percentages of positive events were calculated
above the set threshold from isotype control antibody.
Imaging mouse platelets
A blood sample from each mouse was divided into two 100 ml
aliquots; one was diluted with 100 ml saline (control), the other
with 100 ml saline containing LPS (500 ng/ml final concentration).
Samples were incubated at 25uC. At time-points 0 (prior to LPS or
vehicle), 30 and 60 min, a 20 ml aliquot was removed from each
sample, diluted in 20 ml 2% paraformaldehyde and incubated for
an additional 30 min. Each sample was then diluted in 250 ml PBS
(0.1 mm pore membrane-filtered) and centrifuged at 456g for
12 min. The supernate, which contained platelets, was removed,
placed into a new vial and used for imaging analysis. An aliquot of
each platelet suspension was diluted 1:4 in PBS, and a 25 ml drop
was placed on a glass slide, cover-slipped and sealed with glue.
Platelets were then imaged in dark-field mode using a light
microscope (Olympus BX41 with a 1006 oil-immersion lens)
coupled to a CytoViva illumination system (CytoViva, Inc.,
Auburn, AL). Scanning from a corner of each cover-slip, platelets
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categorized according to shape morphology (discoid, irregular,
flattened, pseudopodia) or whether exhibiting membrane granules
or in aggregates (each aggregate was counted as 1). The number of
platelets in each category was expressed as percentage of total 100
platelets counted.
Analysis of whole blood from in vitro experiments
Diluted (1:100) whole blood (100 mL) was incubated with PE-
conjugated platelet- and leukocyte-specific antibodies (CD41 and
CD45, respectively), or separately with annexin V-FITC (binding
to phosphatidylserine) for 30 min, after which 1% paraformalde-
hyde (400 mL) was added. Matched fluorescein conjugated isotype
control antibodies were used simultaneously staining to set the
threshold and exclude nonspecific binding. Interactions between
cell (platelets or leukocytes) and cell-derived MV and PS
expression on both platelets and leukocytes were analyzed by
flow cytometry (FACSCalibur
TM and FACSCanto
TM, BD Biosci-
ences, San Jose, CA). Platelets were identified by forward and side
scatter and with fluorescein conjugated CD41 antibody until
20,000 events gated for each sample, respectively (Figure 1A).
Microvesicles isolation and analysis
All buffers and antibodies were filtered twice through 0.2 mm
membrane (Millipore) filters for MV analysis. Platelet free plasma
(PFP) was prepared by double centrifugation at 30006g for 15 min.
PFP was diluted (15 mL PFP+85 mL HEPES/HANKS’ buffer) and
incubated with 4 mL FITC-conjugated annexin-V and PE-conju-
gated CD41 or CD45 antibodies for 30 min in dark, at which time
350 mL HANKS’ balanced salts buffer (pH 7.4) with 2.5 mM
CaCl2 was added. Matched isotype control antibodies were used to
set threshold and exclude nonspecific binding. MV were quantified
based on counts of calibration beads (TruCOUNT
TM beads) added
immediately to the samples prior to analysis by flow cytometry
(FACSCanto
TM, BD Biosciences, San Jose, CA) as previously
described [25,26,31]. In this study, MV were defined as events of
,1 mm in diameter using size calibration beads and positive for
annexin-V and platelet- and leukocyte- specific markers.
Analysis of TLR4 intracellular signaling pathway
LPS stimulated TLR4 signaling was analyzed by introducing
MyD88 or TRIF inhibitory peptides as described in other studies
[36,37]. Anticoagulated blood from WT mice was aliquoted into
six tubes and treated with pepinh-control (vehicle), pepinh-MyD
(100 mM, MyD88 inhibitory peptide which binds to MyD88 to
block TLR4 stimulated MyD88 signaling) and/or pepinh-TRIF
(100 mM which binds to TRIF to block TLR4 stimulated TRIF
signaling) alone or in combination for 30 min after which either
saline or LPS (500 ng/mL) was added for one hour. At this time,
an aliquot was diluted for analysis by flow cytometry to measure
cellular origin of MV and platelet positive leukocyte antigen and
leukocyte positive platelet antigen.
Data analyses
Data are presented as percentage or fold increase from the
paired vehicle and LPS treated blood samples at each time point.
All data are presented as mean 6 SEM; n=number of animals
used in each experiment. Statistical significance was evaluated by
paired or unpaired two-tailed Student’s t-test. Statistically
significance was accepted at P,0.05.
Figure 1. Identification of platelets and leukocytes positive for dual cell-specific antigens. A. Representative scatter plot of the gate used
to identify platelets by size. B. Quadrants derived from platelet gate of blood stained with CD41-PE plus IGg-FITC (matched isotype control). C.
Quadrants derived from platelet gate of blood stained with CD41-PE plus CD45-FITC (leukocyte-specific antibody). D & E. Cumulative data of platelets
expressing leukocyte antigen (D) and leukocytes expressing platelet antigen (E) after incubation of blood with LPS (500 ng/mL) for up to 60 minutes.
Data are derived from positive quadrants of platelet and leukocytes gates of scatter plots. WT mice (open bars); dTLR4 mice (closed bars). Data are
expressed as mean 6 SEM (n=8/group) of fold increases from the vehicle-treated group at the same time point. *P,0.05 vs. saline-treated group at
the same time point.
doi:10.1371/journal.pone.0025504.g001
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In vitro experiments
Prior to addition of LPS, platelets from WT mice were discoid,
formed few aggregates and did not have extended psuedopodia
(Figure 2). Surface expression of PS on platelets or leukocytes was
similar in WT and dTLR4 mice. Within each group of mice,
expression of PS was significantly lower on leukocytes than on
platelets (Table 1).
During the first hour of incubation of the blood with LPS,
platelets from WT mice underwent a shape change, extended
pseudopodia and formed aggregates (Figure 2). Within this first
hour, neither surface expression of PS on either platelets or
leukocytes or numbers of platelet- or leukocyte-derived MV
changed significantly in WT mice or dTLR4 mice (Table 1).
However, the number of platelets positive for leukocyte-specific
antigen (defined by the platelet-gate on the flow cytometer,
Figure 1) increased significantly in a time-dependent manner in
blood of WT mice, but not dTLR4 mice (Figures 1). Using the
total leukocyte specific antibody (CD45-APC) to define total
leukocytes, numbers of leukocytes positive for platelet-specific
antigen did not increase significantly in either WT or dTLR4 mice
(Figure 1).
In blood from WT mice, the percentage of platelets positive for
leukocyte antigen (CD45) was reduced significantly and to the
same extent by MyD88 and TRIF (Figure 3). The combination of
MyD88 with TRIF did not reduce the percentage of aggregates to
a greater extent than either alone (from 3.8360.48 to 1.3860.08).
In vivo experiments
Seven days following a single intravenous injection of a sentinel
dose of LPS (20 ng/gm body weight which is 500 ng/mouse),
none of the platelets were positive for leukocyte antigen. On the
contrary, compared to leukocytes obtained from animals treated
with vehicle or a week before LPS injection in the same mouse,
granulocytes and monocytes were significantly positive for platelet
antigen seven days after the single LPS injection (Figure 4).
Apoptotic bodies also stained positive for platelet antigen
(Figure 4).
Discussion
Understanding how infection alters cell-cell interactions and
release of MV from specific blood borne elements may help to
identify new targets for reducing cardiovascular/thrombotic risk
with infection. This study demonstrates the acute, immediate
interaction of platelets and leukocytes after incubation of whole
blood with a sentinel dose of LPS through TLR4 signaling.
Exchange of antigens and associations of specific cell-derived MV
among cells is a mechanism for the transfers signaling molecules to
specific cells. For example, MV derived from neutrophils induced
platelet activation by binding to platelets GP1ba (Glycoprotein 1b
a) via activated aMb2 on MV [38], while platelet-derived MV
mediate leukocyte-leukocyte aggregation, activate leukocyte
phagocytic properties and amplify leukocyte-mediated tissue injury
in thrombotic and inflammatory disorders [39]. Results from the
present study demonstrate that the number of platelets positive for
leukocyte antigen increased within 60 min of exposure to LPS.
This increase was not accompanied by increased expression of PS
on cell or MV surface. Because expression of the leukocyte antigen
on platelets was defined using the platelet size gate and platelet
specific marker CD41 on the flow cytometry, larger leukocytes
would be excluded. Therefore, these leukocyte antigens may
represent a membrane exchange during platelet-leukocyte adhe-
sion or adhesion of leukocyte-derived MV to the platelets. The
half-life of whole platelet-leukocyte aggregates may be shorter and
therefore, we did not determine whole platelet-leukocyte aggre-
gates in this study.
With agonist binding, the TLR4 dimerizes and undergoes a
conformational change required for the recruitment of signaling
molecules [40], such as the adaptor molecules myeloid differen-
tiation protein 88 (MyD88) and Toll-interleukin-1(IL-1) receptor
Figure 2. Representative dark-field micrographs of platelets from a WT mouse taken immediately before or after 30 and 60 min.
incubation of the blood with 500 ng/ml LPS. Prior to LPS application, platelet aggregates (of more than 5 platelets) were absent, and most platelets
were discoid shaped (Left panels). At 30 and 60 minutes incubation with saline, platelet morphology did not change (Top panels); whereas, large
aggregates of irregularly-shaped platelets were observed in those incubated with LPS (bottom panels, inset shows platelets with pseudopodia). Each
bar represents 5 mm. Similar results were observed with blood from two additional animals (n=3).
doi:10.1371/journal.pone.0025504.g002
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mediate MyD88 dependent or independent pathway respectively
[41,42]. LPS activates both MyD88 and TRIF pathways, which
are important in the TLR4 mediated intracellular signaling [42].
The acute effects of LPS on platelet and leukocyte activation were
most likely mediated through activation of TLR4 as platelet
positive leukocyte antigen was not observed in blood from dTLR4
mice. Furthermore, leukocyte antigen expression on platelet was
reduced by inhibition of MyD88- and TRIF-dependent pathways
alone or in combination. These signaling pathways may be
potential molecular targets to inhibit infection/inflammation
induced interactions among formed elements in the blood.
A single TLR4 sentinel dose injection of LPS, such as used in
this study, shortened platelet half-life and increased platelet
production without increases in cytokine production within
3 hours of stimulation [14]. Although in vivo interaction of platelet-
and leukocyte-aggregates with the vascular wall could stimulate or
exacerbate proinflammatory immune responses [43,44], the half-
life of these cell aggregates is not known. A significant finding of
the present in vivo study is that leukocytes sustain or retain platelet
antigen seven days after an in vivo injection of LPS. This time point
corresponds to turnover of the platelet pool and is consistent with
observations that changes in platelet half-life and increases in
platelet turnover are dependent on the concentration of agonist,
i.e. LPS, activation [13,14]. Quantification of dual-positive events
is usually not considered in studies of cellular or MV quantification
with LPS stimulation. Results from the present study, therefore,
suggest that platelet-leukocyte antigen could be used as an
additional biomarker of cellular activation for diagnostic or
prognostic purposes in settings of sub-clinical or asymptomatic
exposures to infective agents.
Monocytes showed the greatest expression of platelet antigen
following LPS injection. Since monocytes are considered to be the
primary leukocytic cell involved with development of atheroscle-
rotic lesions [45,46,47], the present results provide insight into a
mechanism linking low to moderate levels of infection to
progression of cardiovascular disease.
To our knowledge, results of the present study represent the first
to examine time-dependent changes in production of MV/
exchange of cell-specific antigens in cells derived from whole
blood incubated with LPS. In diluted blood, addition of LPS
(500 ng or 1 mg/mL) increased the number of MV from platelets
and those positive for tissue factor but only after four hours of
incubation [34]. Because the blood was diluted, unlike the present
study, cell-cell interactions were most likely attenuated and no
evaluation was performed relative to interaction with leukocytes
which could have indirectly affected platelet activation and
production of cytokines.
Unexpectedly, PS expression on platelets (or leukocytes) did not
increase significantly with acute exposure to LPS. PS is expressed
in the inner leaflet of plasma membrane but rapidly inverts to
outer surface following activating stimuli [48,49,50]. Exposure of
PS to the outer membrane surface also occurs with release of MV
[51]. Results of the present study are consistent with reports that
production of MV is not accompanied by PS expression on cell of
origin but might be restricted to that portion of the membrane
undergoing MV blebbing [52].
Conclusion
Within one hour of exposure of whole blood to a concentration
of LPS that has threshold effect on cytokine production in vivo,
platelets become positive for leukocyte antigen. Platelet-leukocyte
interactions require TLR4 signaling as the dual antigen positivity
of platelets was observed in blood derived from wild type but not
dTLR4 mice. Furthermore, peptide inhibitors of TLR4 signaling
molecules blocked the interaction. These events occur within
Table 1. Expression of PS aggregates and plasma MV before and after treatment with LPS (500 ng/ml for 60 minutes).
Control LPS (500 ng/ml; 60 min)
PS Expression (%)
Plasma MV (counts/m L
plasma) PS Expression (%)
Plasma MV (counts/m L
plasma)
WT Platelet 4.1661.54 (n=7) 33.42610.24 (n=7) 2.5161.01 (n=4) 49.64612.27 (n=6)
WT Leukocyte 0.1060.05 (n=7)* 22.2162.64 (n=7) 0.0860.05 (n=4)* 27.1462.81 (n=4)
dTLR4 Platelet 3.5060.87 (n=7) 25.0963.68 (n=9) 2.8360.64 (n=5) 43.46618.11 (n=4)
dTLR4 Leukocyte 0.0760.03 (n=7)* 22.4562.05 (n=9) 0.0460.008 (n=5)* 31.1762.43 (n=4)
Data shown as mean 6 SEM; PS, phosphatidylserine; MV, microvesicles; LPS, lipopolysaccharide; WT, wild type; dTLR4, gene deleted toll-like receptor 4.
*denote the significant difference in PS expression between platelets and leukocytes in the same genotype mice (p,0.05).
doi:10.1371/journal.pone.0025504.t001
Figure 3. Quantification of platelets positive for leukocyte
antigens using FASCalibur
TM flow cytometry set to the platelet
gate after incubation with inhibitory peptides. Cumulative
changes in number of platelets positive for leukocyte antigens after
incubation of whole blood with saline or LPS (500 ng/mL; for 60 min), in
the absence or presence of control (100 mM) or inhibitory peptides
MyD88 and TRIF (100 mM each). Data are expressed as mean 6 SEM
(n=8/group). *P,0.05 vs. saline-treated group, {P,0.01 vs. control
peptide-treated group incubated with LPS.
doi:10.1371/journal.pone.0025504.g003
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stimulation are sustained at least up to 7 days past the initial LPS
exposure, as leukocytes express platelet antigen at this time point.
Collectively, these results identify an acute and rapid signaling
mechanism by which sentinel-grade acute infection through TLR4
alters blood hemostasis and sustained leukocyte activation which
may contribute to progression of cardiovascular diseases.
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